Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Inventory (2022 - 2025)

Historic Change in Inventory for Whitehawk Therapeutics (WHWK) over the last 4 years, with Q1 2025 value amounting to -$170000.0.

  • Whitehawk Therapeutics' Change in Inventory rose 6530.61% to -$170000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$328000.0, marking a year-over-year decrease of 12588.79%. This contributed to the annual value of -$1.1 million for FY2024, which is 13418.07% down from last year.
  • According to the latest figures from Q1 2025, Whitehawk Therapeutics' Change in Inventory is -$170000.0, which was up 6530.61% from -$158000.0 recorded in Q4 2024.
  • In the past 5 years, Whitehawk Therapeutics' Change in Inventory registered a high of $2.2 million during Q4 2023, and its lowest value of -$630000.0 during Q3 2024.
  • Moreover, its 4-year median value for Change in Inventory was $7000.0 (2022), whereas its average is $295384.6.
  • Data for Whitehawk Therapeutics' Change in Inventory shows a peak YoY increase of 86138.61% (in 2023) and a maximum YoY decrease of 470000.0% (in 2023) over the last 5 years.
  • Whitehawk Therapeutics' Change in Inventory (Quarter) stood at $1.1 million in 2022, then soared by 97.43% to $2.2 million in 2023, then crashed by 107.1% to -$158000.0 in 2024, then fell by 7.59% to -$170000.0 in 2025.
  • Its last three reported values are -$170000.0 in Q1 2025, -$158000.0 for Q4 2024, and -$630000.0 during Q3 2024.